Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials

被引:51
作者
Armon, C [1 ]
Moses, D [1 ]
机构
[1] Loma Linda Univ, Clin Res Ctr, Dept Neurol, Loma Linda, CA 92354 USA
关键词
survival; maximal voluntary isometric contraction; forced vital capacity; Kaplan-Meier method; Cox proportional hazards model;
D O I
10.1016/S0022-510X(98)00196-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Maximal voluntary isometric grip and foot dorsiflexion (FD) strength and forced vital capacity (FVC) were obtained in 62 patients with ALS at or close to enrollment into two clinical trials. The agents tested did not slow disease progression. Isometric strength data were standardized, and the worse side was taken. FVC was expressed as a percentage of the predicted value (FVC%). We derived linear estimates of rates of disease progression based on the isometric myometry and FVC measures and on disease duration. Forty one patients were known to have died or to have undergone tracheostomy for ventilatory support. Probability of tracheostomy-free survival was calculated using the Kaplan-Meier method. The measured values, the linear estimates for rates of decline of these values, gender, age at onset, bulbar vs. spinal onset, height and weight were tested as risk factors within the Cox proportional hazards model, using regression techniques. When tested individually, estimates of rates of decline based on all three measures (FD, grip and FVC%) were the only statistically significant risk factors (P<0.005). Multivariate analysis resulted in a 3-variable model (chi-square=75.3, P<0.00001) in which estimated rates of decline of FD strength and of FVC%, and bulbar onset were independently significant (P<0.0001, P<0.0007 and P<0.05, respectively). We conclude that linear estimates of the rate of disease progression till enrollment into a clinical trial may be better predictors of patient survival than demographic data or discrete biologic measures. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:S37 / S41
页数:5
相关论文
共 9 条
[1]   USE OF COMPOSITE SCORES (MEGASCORES) TO MEASURE DEFICIT IN AMYOTROPHIC LATERAL SCLEROSIS [J].
ANDRES, PL ;
FINISON, LJ ;
CONLON, T ;
THIBODEAU, LM ;
MUNSAT, TL .
NEUROLOGY, 1988, 38 (03) :405-408
[2]  
ARMON C, 1994, HDB NEUROEPIDEMIOLOG, P407
[3]  
BRADLEY WG, 1997, NEUROLOGY, V48, P1728
[4]  
BROOKS BR, 1991, ADV NEUROL, V56, P521
[5]  
BRYAN WW, 1995, NEUROLOGY, V45, pA280
[6]   A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis [J].
Miller, RG ;
Petajan, JH ;
Bryan, WW ;
Armon, C ;
Barohn, RJ ;
Goodpasture, JC ;
Hoagland, RJ ;
Parry, GJ ;
Ross, MA ;
Stromatt, SC ;
Belsh, JM ;
Buchman, AS ;
Donofrio, PD ;
Eisen, AA ;
Gan, RA ;
Gutmann, L ;
Horowitz, SH ;
Jackson, WS ;
Johnston, WS ;
Kelly, JJ ;
Malta, E ;
Mandler, RN ;
Massey, JM ;
McGuire, D ;
Newman, DS ;
Pascuzzi, RM ;
Phillips, LH ;
Ravits, JM ;
Rivner, MH ;
Rubin, M ;
Russo, LS ;
Sergay, SM ;
Sumner, AJ ;
Swenson, MR ;
Teitel, L .
ANNALS OF NEUROLOGY, 1996, 39 (02) :256-260
[7]  
MUNSAT TL, 1991, ADV NEUROL, V56, P515
[8]   RECOMBINANT GROWTH-HORMONE TREATMENT OF AMYOTROPHIC-LATERAL-SCLEROSIS [J].
SMITH, RA ;
MELMED, S ;
SHERMAN, B ;
FRANE, J ;
MUNSAT, TL ;
FESTOFF, BW .
MUSCLE & NERVE, 1993, 16 (06) :624-633
[9]  
STRAMBLER N, 1998, NEUROLOGY, V50, P66